Paul Jeng
Stock Analyst at Guggenheim
(1.19)
# 3,697
Out of 4,595 analysts
26
Total ratings
52.2%
Success rate
-1.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintained: Buy | $10 | $3.75 | +166.67% | 5 | Jul 14, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $45 | $8.97 | +401.67% | 2 | Jun 2, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $54 | $35.50 | +52.11% | 7 | Jun 2, 2026 | |
| IMTX Immatics | Maintained: Buy | $19 | $8.66 | +119.40% | 5 | May 12, 2026 | |
| CHRS Coherus Oncology | Initiated Coverage: Buy | $12 | $1.41 | +751.06% | 1 | May 11, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $5 | $0.5994 | +734.17% | 4 | May 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $33.81 | - | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $3.92 | n/a | 1 | Jul 29, 2020 |
Adagene
Jul 14, 2026
Maintained: Buy
Price Target: $10
Current: $3.75
Upside: +166.67%
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Maintained: Buy
Price Target: $45
Current: $8.97
Upside: +401.67%
IDEAYA Biosciences
Jun 2, 2026
Maintained: Buy
Price Target: $54
Current: $35.50
Upside: +52.11%
Immatics
May 12, 2026
Maintained: Buy
Price Target: $19
Current: $8.66
Upside: +119.40%
Coherus Oncology
May 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $1.41
Upside: +751.06%
Context Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.5994
Upside: +734.17%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $33.81
Upside: -
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $3.92
Upside: n/a